Tysabri is a medicine used to treat certain types of multiple sclerosis and Crohn's disease. It's a special type of medicine called a monoclonal antibody. It works by helping the body's immune system fight off the inflammation that causes these diseases. It's taken as an injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Tysabri (Natalizumab) for MS (Multiple Sclerosis)?
Natalizumab, sold as Tysabri, is a prescription medicine given by infusion into a vein for two immune-driven diseases in adults. In multiple sclerosis (MS), it is used on its own to treat relapsing forms of the disease: clinically isolated syndrome (a first episode of MS-type nerve symptoms), relapsing-remitting MS, and secondary progressive MS that is still active. Its job is to prevent relapses and slow the build-up of disability. It is also approved for adults with moderate to severe Crohn's disease, an inflammatory bowel disease, who still have active inflammation after standard treatments and TNF (tumor necrosis factor) blockers (a common group of biologic medicines for Crohn's) have not worked or could not be tolerated. Natalizumab works well, but it carries a risk of PML (progressive multifocal leukoencephalopathy), a rare and serious brain infection explained below. Deciding to start it, and to keep going, means weighing its benefit against each person's own PML risk. Tyruko (natalizumab-sztn) is a biosimilar version from another manufacturer, approved for the same uses and available in the US since late 2025.
Natalizumab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. Its target is alpha-4 integrin, a molecule on the surface of most white blood cells. Integrins act as anchors that let immune cells grip the lining of blood vessels and then pass through the vessel wall into nearby tissue. In MS, damage begins when activated immune cells cross the barrier between the bloodstream and the brain and spinal cord and set off inflammation there. By blocking alpha-4 integrin, natalizumab keeps many of these cells from getting through, so fewer new areas of inflammation form. In Crohn's disease, it blocks a related route that immune cells use to enter the gut wall. Researchers have not fully worked out every step of how this produces the benefit. The same effect explains the main risk. Limiting immune cells' access to the brain also weakens its defense against infection, which is how a normally harmless virus can cause PML.
Natalizumab is given as an infusion through a vein, 300 mg over about an hour once every four weeks, at an infusion center certified to give it. It is not a pill or a home injection. Staff watch you during each infusion and for one hour afterward for at least the first 12 infusions, because allergic reactions are most likely within two hours of starting. Because of the PML risk, US prescribers, infusion centers and patients must all enroll in a restricted safety program (TOUCH for Tysabri, and a separate program for Tyruko). Before each infusion you answer questions about new symptoms and infections, and the prescriber must reauthorize treatment every six months. People with MS have a brain MRI (magnetic resonance imaging) scan before starting, so later scans can be compared against it. Keeping to the schedule matters. If you miss an infusion, contact the care team to reschedule promptly. A long unplanned break, especially after only one or two infusions, raises the chance of developing antibodies against the drug, which can cause allergic reactions and make it work less well. Some MS specialists lengthen the gap to every six weeks to try to lower PML risk. This is not the labeled schedule. In a trial of people whose MS was stable, most stayed well controlled on six-week dosing, and observational data link it to fewer PML cases, though pooled studies found slightly more new inflammation on MRI. It should only be done as a deliberate plan with the neurologist.
Headache and tiredness are the most common side effects. Joint pain, pain in the arms or legs, rash, stomach discomfort and diarrhea are also more frequent than with placebo, as are everyday infections such as urinary tract, chest, tooth and vaginal infections. These are usually manageable without stopping treatment. Allergic reactions to the infusion are uncommon but can be serious. They usually begin within two hours and can include hives, itching, flushing, fever, chills, dizziness, nausea or chest pain. Tell the infusion staff right away. If trouble breathing or swallowing starts after you have left, call 911. Anyone who has had a reaction should not receive natalizumab again. A few rarer problems need quick action. Sudden fever with a severe headache and confusion can signal a herpes virus infection of the brain or its lining, which can be fatal; get emergency care. Contact the care team right away for vision changes, eye redness or eye pain (a herpes infection of the retina can cause blindness), yellowing of the skin or eyes or dark urine (liver injury), unusual bruising, bleeding or tiny red or purple spots on the skin (low platelets), or signs of infection such as fever, chills, cough or painful urination.
PML is a brain infection caused by the JC virus, a common virus that many people carry without symptoms. When immune defenses are weakened, it can attack the brain. PML usually leads to death or severe disability, and there is no reliable way to prevent or treat it, so it shapes every decision about natalizumab. Three things raise the risk: a blood test showing antibodies to the JC virus (a sign of past infection), longer treatment, especially beyond two years, and earlier use of immune-suppressing drugs such as mitoxantrone, azathioprine or methotrexate. US estimates put the risk at about 1 in 10,000 for people who test negative, and roughly 2 to 7 in 1,000 for people who test positive and have been treated longer than two years. A negative result is not permanent: 3 to 8 percent of people with MS turn positive each year, so the test is repeated during treatment. PML symptoms build over days to weeks and can look like an MS relapse: weakness on one side of the body that keeps getting worse, clumsiness of the arms or legs, vision changes, and changes in thinking, memory, personality or orientation. Call the prescriber right away about any new or worsening symptom, during treatment and for at least six months after the last dose. Infusions are held until PML has been ruled out with an MRI and sometimes a spinal fluid test. Natalizumab is not combined with other drugs that suppress the immune system. In Crohn's disease it should not be given with azathioprine, 6-mercaptopurine, methotrexate, cyclosporine or TNF blockers, and long-term steroids are tapered off. Tell the team about any condition that weakens the immune system, such as HIV, cancer of the blood or an organ transplant, and check before any vaccination. People who have ever had PML, or a past allergic reaction to natalizumab, should not take it. Human pregnancy data are limited. Babies exposed in the womb have been born with low platelets and anemia, so the baby's doctor should know and check a blood count. Stopping natalizumab before or during pregnancy can let MS relapses return, so plan with the neurologist before trying to conceive. Natalizumab passes into breast milk, and its effect on a nursing baby is unknown.
In the main two-year MS trial, people taking natalizumab had about two-thirds fewer relapses than people given a placebo, and fewer had disability that worsened and stayed worse (17 percent versus 29 percent). MRI scans also showed far fewer new areas of inflammation. It controls MS rather than curing it, and response varies from person to person. In Crohn's disease, improvement is expected within the first few months. If there is no benefit by 12 weeks, or if long-term steroids cannot be stopped within six months, natalizumab is discontinued. Treatment settles into a routine of monthly infusions and regular check-ins: prescriber visits at three and six months and then every six months, repeat JC virus antibody tests for people who were negative, and periodic MRI scans. Each review is a chance to reconsider whether the benefit still outweighs the PML risk, which grows over time for people who test positive. Stopping needs a plan. MS activity often returns within months of the last infusion, so the next treatment is usually lined up so the gap is no longer than about three months. PML can still appear after stopping, so watching for symptoms continues for at least six months.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Tysabri (Natalizumab), what you've noticed, or ask the community a question.